Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Successful response to infliximab of recurrent pericardial graft versus host disease in a pediatric patient

Bone Marrow Transplantation volume 48, pages 144–145 (2013)Cite this article

Subjects

Allogeneic hematopoietic SCT (HSCT) is the only curative treatment for many malignant and non-malignant diseases. As survival improves, the frequency of late effects, among which chronic GVHD (cGVHD) is the most significant, also increases.1

cGVHD may affect any organ in the body, with a behaviour resembling an autoimmune disease, including serositis (pleural/pericardial effusion and ascites).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2006; 12: 138–151.

    Article  Google Scholar 

  2. Walsh RF, Chowdhury D . Incessant pericardial effusion in a 9 year old male responding to infliximab. Cardiol Young 2009; 19: 413–415.

    Article  Google Scholar 

  3. David A . Jacobsohn Optimal management of chronic graft-versus-host disease in Children. Br J Haematol 2010; 150: 278–292.

    Article  Google Scholar 

  4. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  Google Scholar 

  5. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  Google Scholar 

  6. Imazio M, Mayosi BM, Brucato A, Markel G, Trinchero R, Spodick DH et al. Triage and management of pericardial effusion. J Cardiovasc Med 2010; 11: 928–935.

    Article  Google Scholar 

  7. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443–1453.

    Article  CAS  Google Scholar 

  8. Sleight BS, Chan KW, Braun TM, Serrano A, Gilman AL . Infliximab for GVHD therapy in children. Bone Marrow Transplant 2007; 40: 473–480.

    Article  CAS  Google Scholar 

  9. Rodriguez V, Anderson PM, Trotz BA, Arndt CA, Allen JA, Khan SP et al. Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut. Pediatr Blood Cancer 2007; 49: 212–215.

    Article  Google Scholar 

  10. Rao K, Rao A, Karlsson H, Jagani M, Veys P, Amrolia PJ et al. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease. J Pediatr Hematol Oncol 2009; 31: 456–461.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unidad de Hemato-Oncología y Trasplante de Progenitores Hematopoyéticos Pediátrica, Hospital Universitario La Paz, Madrid, Spain

    P M Rubio, S Riesco, D Plaza, B González, G M Muñoz & A Sastre

  2. Servicio de Cardiología Pediátrica, Hospital Universitario La Paz, Madrid, Spain

    C Labrandero

Authors
  1. P M Rubio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Labrandero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Riesco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Plaza
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B González
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G M Muñoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Sastre
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P M Rubio.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rubio, P., Labrandero, C., Riesco, S. et al. Successful response to infliximab of recurrent pericardial graft versus host disease in a pediatric patient. Bone Marrow Transplant 48, 144–145 (2013). https://doi.org/10.1038/bmt.2012.91

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.91

Search

Advanced search

Quick links